Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies

• Authors: WEIRAUCH Ulrike; KREUZ Markus; BIRKENBIHL Colin; ALB Miriam; QUARANTA Maria; CALZONE Laurence; OROZCO-RUIZ Sophia; BINDER Stefanie; FISCHER Luise; CLAVREUL Solene; MAGURI Morine; FERLE Maximilian; RADE Michael; AZARIAS Guillaume; HYDREN Jay R; JAMÁRIK Jakub; SCHWARZ Daniel; SEBESTYEN Zsolt; KUBALL Jurgen; POPP Georg; ANTOINE Chloe; KNOCKAERT Manon; SCHOEDER Clara T; FANDREI David; SANGES Carmen; RADVILAS Vaclovas; GAGELMANN Nico; RUECKERT Markus; PENACK Olaf; FRICKE Stephan; SCHMIDT Andreas; WARD Carol; STEINBEISSER Carl; JEAN-MARC Van Gyseghem; NIARAKIS Anna; GARDERET Laurent; HUDECEK Michael; NEUMUTH Thomas; PLATZBECKER Uwe; KOEHL Ulrike; DEMLOVÁ Regina; KREMER Andreas; FRANKE Stefan; FROEHLICH Holger; MERZ Maximilian; REICHE Kristin
• Year of publication: 2025
• Type: Article in Periodical
• Magazine / Source: NPJ DIGITAL MEDICINE
• MU Faculty or unit: Faculty of Medicine
• web: https://www.nature.com/articles/s41746-025-01809-6
• Doi: https://doi.org/10.1038/s41746-025-01809-6
• Keywords: biomedical virtual twins; engineered adoptive cellular immunotherapies
• Description: In (immune)oncology, virtual twins (VTs) offer patient-individual decision support. Nevertheless, current VTs do not incorporate the unique properties of engineered adoptive cellular immunotherapies (eACIs). Here, we outline the minimal design specifications for VTs for engineered ACIs (eACI-VTs) to model the complex interplay between cell product and patient physiology. We motivate utilizing VTs in eACIs to provide decision support and reflect on how eACI-VTs can support the widespread use of eACIs.